The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

Right around the be­gin­ning of the year, we got a close-up look at what hap­pens af­ter a boom rip­ples through biotech. The crash of life sci­ences stocks in Q1 was heard around the world.

In the months since, we’ve seen the nat­ur­al Dar­win­ian down cy­cle take ef­fect. Re­verse merg­ers made a come­back, with more burned out shells to go pub­lic at a time IPOs and road shows are out of fa­vor. And no doubt some of the more re­cent ar­rivals on the in­vest­ing side of the busi­ness are find­ing green­er pas­tures.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN